CASI Pharmaceuticals (CASIF) Enterprise Value (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Enterprise Value came in at -$5.6 million in Q4 2025, up 58.42% YoY from -$3.5 million in Q4 2024, and down 19.53% on a QoQ basis from -$4.7 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Enterprise Value (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Enterprise Value data on file, last reported at -$5.6 million in Q4 2025.
- Quarterly Enterprise Value rose 58.42% year-over-year to -$5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.6 million (up 58.42% YoY) and the FY2025 annual result came in at -$5.6 million, up 58.42% from the prior year.
- Enterprise Value retreated to -$5.6 million in Q4 2025, from -$4.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $1.8 billion in Q2 2023 to a low of -$48.6 million in Q4 2021.
- A 5-year average of $133.6 million and a median of -$9.5 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 99.91% in 2025, down 70601.77% in 2025.
- Tracing CASIF's Enterprise Value over 5 years: stood at -$48.6 million in 2021, then surged by 46.03% to -$26.2 million in 2022, then declined by 10.98% to -$29.1 million in 2023, then surged by 53.71% to -$13.5 million in 2024, then jumped by 58.42% to -$5.6 million in 2025.
- The last three Enterprise Value figures came in at -$5.6 million (Q4 2025), -$4.7 million (Q3 2025), and -$6.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | -3.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.60 Mn |
| Sep 30, 2025 | -4.69 Mn |
| Jun 30, 2025 | -6.74 Mn |
| Mar 31, 2025 | -10,897.00 |
| Dec 31, 2024 | -13.47 Mn |
| Sep 30, 2024 | -16.54 Mn |
| Jun 30, 2024 | -9,533.00 |
| Mar 31, 2024 | -12.20 Mn |
| Dec 31, 2023 | -29.09 Mn |
| Jun 30, 2023 | 1.77 Bn |
| Dec 31, 2022 | -26.22 Mn |
| Dec 31, 2021 | -48.57 Mn |